Crescendo Biologics Ltd.

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

Kriya Therapeutics, Inc. raised a $270m series C round in May 2022 with plans to take its first gene therapy candidates into the clinic in 2023. Now that the company has added more than $150m to that

Who: BioNTech SE/Ryvu Therapeutics What: Ryvu licenses its STING agonist portfolio to BioNTech and also inks a multi-target research collaboration to advance small molecule immune modulators for ca

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bristol Partners With Century On Cancer